Apatinib as an optional treatment in metastatic colorectal cancer

Antiangiogenic therapy has shown clinical benefit in metastatic colorectal cancer (mCRC). We aimed to evaluate the efficacy and safety of apatinib in patients who failed standard treatment and to explore potential factors related to its efficacy. A total of 47 patients were enrolled in this retrospe...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Aiyi, Wang, Kong, Xu, Aiguo, Wang, Gang, Miao, Yongchang, Sun, Zhichao, Zhang, Jingyu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2019
Materias:
5700
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6736175/
https://www.ncbi.nlm.nih.gov/pubmed/31464927
http://dx.doi.org/10.1097/MD.0000000000016919

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6736175/
https://www.ncbi.nlm.nih.gov/pubmed/31464927
http://dx.doi.org/10.1097/MD.0000000000016919

Ejemplares similares